ALTEOGEN Inc. (KOSDAQ:196170)

Market Cap	17.49T -2.3%
Revenue (ttm)	203.76B +34.4%
Net Income	130.19B +4.6%
EPS	1,960.14 -8.3%
Shares Out	53.56M
PE Ratio	166.57
Forward PE	50.37
Dividend	371.00 (0.13%)
Ex-Dividend Date	Dec 29, 2025

Volume	753,141
Open	292,000
Previous Close	289,500
Day's Range	287,500 - 340,000
52-Week Range	286,000 - 569,000
Beta	0.93
Analysts	Buy
Price Target	458,000.00 (+40.28%)
Earnings Date	Aug 11, 2026

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196170

Financial Performance

In 2025, ALTEOGEN's revenue was 215.86 billion, an increase of 109.87% compared to the previous year's 102.85 billion. Earnings were 141.67 billion, an increase of 127.57%.

Analyst Summary

According to 5 analysts, the average rating for 196170 stock is "Buy." The 12-month stock price target is ₩458,000, which is an increase of 40.28% from the latest price.

Price Target

₩458,000

(40.28% upside)

Analyst Consensus: Buy